A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Trial Profile

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 16 Jun 2015 Planned number of patients changed from 100 to 80 as reported by ClinicalTrials.gov.
    • 16 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top